A prospective, nonrandomized clinical study of patients with chronic total occlusion lesions (CTO) treated with everolimus-eluting scaffolds: A study of Poznan CTO-Absorb Registry

Trial Profile

A prospective, nonrandomized clinical study of patients with chronic total occlusion lesions (CTO) treated with everolimus-eluting scaffolds: A study of Poznan CTO-Absorb Registry

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2017 New trial record
    • 02 Nov 2017 Results of subgroup analysis (n=65) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 02 Nov 2017 Results presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top